Physician Views: FirstWord is polling endocrinologists and primary care physicians about their usage of the SGLT2 inhibitor class for type 2 diabetes and the potential impact of a cardiovascular (CV) label claim for Jardiance

Back in June, an FDA advisory panel voted closely in favour that substantial evidence exists to establish that Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance (empagliflozin) reduces cardiovascular death in adults with type 2 diabetes and established CV disease. The companies are now awaiting confirmation from the agency - scheduled within the next 10 days - as to whether labelling for the drug will be updated to reflect this.

Data from the EMPA-REG study, first published around a year ago, was met with positive feedback from physicians polled by FirstWord at the time. Our latest Physician Views poll provides an assessment of current second- and third-line use of the SGLT2 inhibitor class, how data from EMPA-REG has impacted adoption and what impact an updated label may have on usage of Jardiance. Specifically, we are asking endocrinologists and primary care practitioners – who are based in both the US and EU5 markets – the following questions…

How comfortable are you using an SGLT2 inhibitor as a second-line therapy for type 2 diabetes (i.e. after failure with metformin)?

Not comfortable

Marginally comfortable

Moderately comfortable

Very comfortable

Extremely comfortable

Which of the following acts as the primary factor in preventing you from treating a type 2 diabetes patient with an SGLT2 inhibitor in the second-line setting (i.e. after metformin)?

Efficacy profile

Safety profile

Mechanism of action

Price

Lack of access/coverage

Lack of experience/education with drug class

Other (please state)

How comfortable are you using an SGLT2 inhibitor in the third-line setting for type 2 diabetes (i.e. after failure with metformin and a DPP-4 inhibitor)?

Not comfortable

Marginally comfortable

Moderately comfortable

Very comfortable

Extremely comfortable

Has positive data from the EMPA-REG cardiovascular outcomes study made you prescribe Jardiance more frequently in the past year?

No

Yes – marginally so

Yes – moderately so

Yes – significantly so

Yes – very significantly so

If Jardiance secures a label claim for reduction in cardiovascular death in adults with type 2 diabetes and established cardiovascular disease would this make you more likely to use the drug as a second-line therapy for type 2 diabetes?

No

Yes – marginally so

Yes – moderately so

Yes – significantly so

Yes – very significantly so

Results and related analysis will be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com

To read more Physician Views articles, click here.